Canakinumab pre-filled syringe + Canakinumab lyophilized powder + Triamcinolone Acetonide + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Gouty Arthritis
Conditions
Acute Gouty Arthritis
Trial Timeline
May 1, 2011 → Sep 1, 2012
NCT ID
NCT01356602About Canakinumab pre-filled syringe + Canakinumab lyophilized powder + Triamcinolone Acetonide + Placebo
Canakinumab pre-filled syringe + Canakinumab lyophilized powder + Triamcinolone Acetonide + Placebo is a phase 3 stage product being developed by Novartis for Acute Gouty Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT01356602. Target conditions include Acute Gouty Arthritis.
What happened to similar drugs?
20 of 20 similar drugs in Acute Gouty Arthritis were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01356602 | Phase 3 | Completed |
Competing Products
20 competing products in Acute Gouty Arthritis